Filing Flows › Northwest Biotherapeutics (NWBO) › Q1 2026 › vs Q1 2025
Northwest Biotherapeutics (NWBO) Q1 2026 vs Q1 2025 (year over year)
Northwest Biotherapeutics's revenue rose $119K (+32%) from $375K in Q1 2025 to $494K in Q1 2026.
Northwest Biotherapeutics, Q1 2026: revenue $494K (+32% year over year), net earnings $3.1M, operating cash flow −$12.5M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $494K | $375K | $119K | +32% |
| Other income, net | $14.0M | −$2.0M | $16.0M | — |
| Costs & expenses | $14.5M | $19.7M | −$5.2M | -26% |
| Operating costs | $11.4M | $17.7M | −$6.3M | -36% |
| Net earnings | $3.1M | −$19.3M | $22.4M | — |
| Research & development | $4.9M | $8.4M | −$3.5M | -42% |
| General & admin | $6.5M | $9.3M | −$2.8M | -30% |
| Operating cash sources | $16.7M | −$9.1M | $25.8M | — |
| Depreciation & amortization | $771K | $400K | $371K | +93% |
| Share-based compensation | $288K | $385K | −$97K | -25% |
| Cash used in operations | $12.5M | $9.4M | $3.1M | +33% |
| Working capital & other | $16.7M | −$9.1M | $25.8M | — |
Questions
How much did Northwest Biotherapeutics's revenue grow year over year in Q1 2026?
Northwest Biotherapeutics's revenue rose $119K (+32%) from $375K in Q1 2025 to $494K in Q1 2026.